Gregory J. Fluet serves as Independent Director of the Company. Mr. Fluet is currently Chief Operating Officer for Rebiotix, a Ferring Pharmaceuticals company. Since November 2016 he has worked at Rebiotix in both contract and permanent roles including serving as Chief Business Officer from April 2017 until the company's acquisition by Ferring Pharmaceuticals in April 2018. Prior to that he had a strategic consulting practice working with startup life science companies. He had previously served as chief executive officer at Urologix, Inc., then a public company, from 2012 to January 2016. He also served as its interim chief financial officer from August 2014 to May 2015 and as its executive vice president and chief operating officer from 2008 to 2012. From 2002 to 2008, he was employed as an associate at Sapient Capital Management, LLC, a healthcare focused venture capital fund. He received a BS in Mechanical Engineering from Stanford University. Our Board believes that Mr. Fluet’s experience as an executive officer of medical device companies, sales operations and operations and manufacturing experience and his healthcare related financial and investment experience make him uniquely qualified to serve as a director.
As the Independent Director of Electromed, the total compensation of Gregory Fluet at Electromed is $48,470. There are 6 executives at Electromed getting paid more, with Kathleen Skarvan having the highest compensation of $748,268.
Gregory Fluet is 51, he's been the Independent Director of Electromed since 2019. There are 8 older and 2 younger executives at Electromed. The oldest executive at Electromed Inc. is George Winn, 83, who is the Independent Director.
Gregory's mailing address filed with the SEC is 500 SIXTH AVENUE NW, , NEW PRAGUE, MN, 56071.
Over the last 14 years, insiders at Electromed have traded over $2,585,226 worth of Electromed stock and bought 684,801 units worth $2,582,707 . The most active insiders traders include Oak Partners, Llc Red, Stephen H. Craney et Kathleen Skarvan. On average, Electromed executives and independent directors trade stock every 84 days with the average trade being worth of $358,798. The most recent stock trade was executed by James L. Cunniff on 1 March 2024, trading 9,000 units of ELMD stock currently worth $137,250.
electromed, inc. is a minnesota-based company (nyse mkt: elmd) and the innovative leader in the development, manufacture, and worldwide sales of the smartvest® airway clearance system. the patented system uses high frequency chest wall oscillation (hfcwo), a better-tolerated alternative to chest physiotherapy (cpt), to deliver vigorous, yet comfortable airway clearance treatment for patients battling the consequences of retained secretions. hfcwo has been clinically proven to clear the lungs of excess mucus, improve and reduce lung infections for individuals suffering from various conditions including atelectasis, copd, bronchiectasis, neuromuscular diseases, and cystic fibrosis. electromed, inc. is accredited by the joint commission and is iso 13485:2003 and iso 9001:2008 certified.
Electromed executives and other stock owners filed with the SEC include: